SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of MyoKardia, Inc. (Nasdaq – MYOK)

BALA CYNWYD – October 5, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of MyoKardia, Inc. (“MyoKardia” or the “Company”) (Nasdaq – MYOK) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by Bristol Myers Squibb (NYSE – BMY) in an all-cash transaction. Under the terms of the agreement, MyoKardia stockholders will receive $225.00 in cash per MyoKardia share in the transaction.

The investigation concerns whether the MyoKardia Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether BMY is paying too little for the Company. MyoKardia’s lead product mavacamten, an experimental drug that treats obstructive hypertrophic cardiomyopathy, is already through Phase 3 testing programs and BMY’s CEO has stated it “can be a multi-billion dollar asset.”

If you own shares of MyoKardia stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or call toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.